Aktana Announces First-To-Market GenAI Agents That Survive CRM Transitions
5.12.2024 16:00:00 CET | Business Wire | Press release
Aktana’s New Products Fortify Technology Stacks for the Future
Aktana, Inc., the leader in intelligent customer engagement for the global life sciences industry, today announced the Aktana Action Agent - designed to empower field teams and future-proof omnichannel engagement.
“The major players in Life Sciences CRM systems and Customer Data Platforms (CDPs) are changing roadmaps and partnerships, leaving pharma companies facing a serious innovation challenge.” said Derek Choy, Co-founder and Chief Product Officer of Aktana. “There’s an urgent need to help leaders find future-proofed solutions that address today’s business needs, as they confront expensive migration decisions in this shifting landscape.”
Aktana was recently named a Leader and one of only three Star Performers in the 2024 Life Sciences Next-Generation Customer Engagement Platform (CEP) PEAK Matrix® by Everest Group, cementing Aktana's position as a leading future-proof CEP.
“Life Sciences enterprises are increasingly prioritizing experience-driven Customer Engagement Platforms over traditional CRM systems, reflecting a significant shift towards customer-centric strategies,” said Chunky Satija, Vice President, Healthcare and Life Sciences, Everest Group.
Aktana Action Agent: Strategic Field Activity
Deeply integrated with Aktana’s Strategy Orchestration, Action Agent empowers life sciences teams to make smarter, data-driven decisions – harnessing the power of Large Language Models (LLMs). Purpose-built agents automate critical tasks such as:
1.) streamlining planning with suggested actions (forecasted to improve defined business outcomes);
2.) enabling pre-call preparation with insights tailored for each HCP;
3.) reducing logistical effort with automated call logging.
Faster Time-to-Value with CRM-Agnostic AI
Action Agent can be embedded into popular CRM systems like Veeva and Salesforce, giving customers optionality. Delivering immediate value on existing investments, Aktana ensures seamless migration so that customers are not locked into a siloed ecosystem.
Each agent is pre-configured so it can be deployed and scaled effortlessly, enabling customers to fill critical business gaps without migration delays. By providing a scalable and interoperable solution, Aktana Action Agent drives strategic alignment and delivers faster time-to-value for life sciences organizations.
Sign up for our webinar happening on Dec 12th to learn more about future-proof CRM strategies from our cofounder Derek Choy.
Learn more: Aktana Action Agent
About Aktana
Aktana provides AI-powered solutions tailored to the life sciences industry, enabling commercial teams to align strategies with customer needs, optimize engagement across channels, and deliver measurable impact.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205089781/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom